• Home
  • About
    • Management Team
    • Board of Directors
  • Pipeline
    • CiVi 030
    • CiVi 008
  • Investors
  • News
  • Contact
Menu
  • Home
  • About
    • Management Team
    • Board of Directors
  • Pipeline
    • CiVi 030
    • CiVi 008
  • Investors
  • News
  • Contact
  • Home
  • About
    • About Us
    • Management Team
    • Board of Directors
  • Pipeline
    • CiVi 030
    • CiVi 008
  • Investors
  • News
  • Contact
Menu
  • Home
  • About
    • About Us
    • Management Team
    • Board of Directors
  • Pipeline
    • CiVi 030
    • CiVi 008
  • Investors
  • News
  • Contact

News

2021

CiVi Biopharma to Participate in HC Wainwright BioConnect 2021 Conferences

pdf-file


2020

CiVi Biopharma Resumes AURORA Phase 3 Clinical Trial of CIVI030 to Treat Systemic Sclerosis

pdf-file

2018

CiVi Biopharma Announces Appointment of Shalom Jacobovitz as Chief Executive Officer

pdf-file

2017

CiVi Biopharma Receives Worldwide Exclusive License to Develop a Novel, RNA Targeted Drug Against PCSK-9

pdf-file

CiVi Biopharma Raises $40 Million in Series A Financing From Boxer Capital of the Tavistock Group

pdf-file
Linkedin
  • Home
  • About
  • Pipeline
  • Investors
  • News
  • Contact
Menu
  • Home
  • About
  • Pipeline
  • Investors
  • News
  • Contact
  • Privacy Policy
  • Conditions of Use
  • Site Map
Menu
  • Privacy Policy
  • Conditions of Use
  • Site Map

© 2020 The content on this website is owned by us and our licensors.
Do not copy any content (including images) without our consent.